A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Carlsmed (Nasdaq:CARL) today announced new technology add-on payment (NTAP) reimbursement for its spine implant technology.

Cardiosense receives US FDA 510(k) clearance for its CardioTag device: Chicago Friday, August 1, 2025, 17:00 Hrs [IST] Cardiosense, a medical AI company transforming cardiovascula ...

Science evolves as both controlled clinical research and real-world evidence show us how to use health care technologies to ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts. On July 29, Apellis announced that the US FDA approved EMPAVELI (pegcetacoplan) as the ...

Artificial Intelligence (AI) continues to revolutionize industries and is poised to bring transformative change in healthcare delivery, ...

The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY ...

In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected ...

Eli Lilly's diabetes drug Mounjaro demonstrated superior efficacy to its predecessor Trulicity in reducing heart attack and ...